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Recurrent aphthous stomatitis (RAS) is a disease 
characterized by the periodic appearance of aphthous 
lesions on the oral mucosa, of which etiology and 
physiopathology are not well explained. Recent studies 
with direct immunofluorescence show controversial results. 
Some reveal that the basic disorder is associated with 
humoral immunity, while others point to changes in cellular 
immunity. Atypical forms of aphthous stomatitis may have 
its differential diagnosis carried out with vesicobullous 
diseases, such as pemphigus vulgaris. Aim: Check the 
presence of immunocomplexes in the mucosa of patients 
with aphthous stomatitis and the usefulness of the differential 
diagnosis method with bullous skin diseases. Materials 
and methods: 23 patients with aphthous stomatitis were 
prospectively included in the study. There were all submitted 
to mucosa biopsy under local anesthesia for the removal of 
two fragments. One of these was sent to histology and, the 
other to direct immunofluorescence. Results: The 23 samples 
from the histology exam revealed an ulcerated inflammatory 
process. The samples referred to immunofluorescence 
resulted negative and only one showed the presence of 
complement in the basal membrane. Conclusion: Based 
on our results, we conclude that the patients with RAS do 
not show deposits of immunocomplexes in their oral cavity 
mucosa and immunofluorescence is useful in the differential 
diagnosis between this disease and bullous skin diseases.
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INTRODUCTION
Recurrent Aphthoid Stomatitis (RAS) is a common 
disease of the oral cavity, affecting about 20% of the world’s 
population1, women are more affected than men, and in 
most cases it starts around the first decade of life.
The disease may manifest itself in three different 
ways. The minor type is characterized by a small ulcer, 
measuring from three to ten millimeters in diameter, lo-
cated in the non-keratinized mucosa, alone or even in 
large quantities in the mouth2,3(Figure 1). The major type 
is characterized by an extensive and painful ulcer, mea-
suring more than 10 millimeters in diameter, also present 
in keratinized mucosa, usually alone, and can take more 
than 15 days to heal completely, and it may leave scars 
in the mucosa (Figure 2). The third type is herpes-like, 
characterized by numerous small ulcers that coalesce, and 
this is the rarest form of the disease2,3.
with RAS, based on the fact that T-cells are the ones most 
commonly found in aphthoid lesions. Moreover, another 
piece of data corroborating this hypothesis is a variation 
in the ratio of T cells CD4+ / T CD8+ in the oral mucosa 
affected during its different development stages.
On the other hand, other authors16-18 found IgG and 
C3, during DIf, and they advocate that humoral response 
is present in RAS genesis.
Another important aspect is that, depending on 
their development stage, aphthoid lesions may be similar 
to other bullous, auto-immune diseases, such as pem-
phigus vulgaris (PV) or mucous membrane pemphigoid 
(MMP)21. However, it is known that these diseases are 
provenly positive in DIf - PV with intra-epithelial depo-
sits of immunoglobulins and MMP with similar deposits 
in the basal membrane22. Thus, DIf in patients with RAS, 
especially in its typical forms, and if it is shown negative, 
would have an important role in the differential diagnosis 
of these diseases.
OBJECTIVES
1) try to show the presence or absence of immu-
noglobulins in the perilesional mucosa of patients with 
RAS, through DIf, in order to add data to the hypothesis 
that the disease’s physiopathology would or would not be 
connected to the alterations in humoral immunity and
2) check if DIf has a relevant role in the differential 
diagnosis of RAS and vesicobullous diseases such as PV 
and MMP.
MATERIALS AND METHODS
In this present investigation we had 23 consecutive 
patients with RAS, who reported having at least one epi-
Figure 1. Aphtha minor on the tongue’s lateral border
Despite its unknown etiology, many are the factors 
associated with or that may trigger RAS outbreaks. Among 
them we list: immune disorders4, blood deficiency2,3,5,6, 
vitamin deficiency7, hypersensitivity to food8, zinc defi-
ciency9, psychological factors10, genetic factors11, infectious 
and viral factors12,13 and rheumatic disease14.
The main physiopathological hypothesis for the ori-
gin of RAS lesions are associated with humoral or cellular 
immunity4,15-20. Most of the studies aforementioned, among 
other exams, used direct immunofluorescence (DIf) in 
order to try to prove the presence or absence of immuno-
complex deposits on the mucosa of patients with RAS.
Lehner15 and Sistig et al.4 advocate the thesis that 
RAS’s physiopathology is associated with a disorder in im-
munomodulation. These authors did not find positiveness 
in the direct immunofluorescence test (DIf) in patients 
Figure 2. Aphtha major on the lower lip. Notice scar lesions
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sode of aphtha per month, for a minimum period of two 
years. The study ran from March 2004 to may 2006, with 
historical and cross-sectional cohort design.
The patients signed an informed consent form and 
the study was approved by the institution’s ethics com-
mittee under protocol number 876/04, as part of a larger 
project to investigate clinical, laboratorial and genetic 
aspects of patients with RAS.
All patients were submitted to a protocol based on 
otorhinolaryngological general anamnesis, physical exam, 
especially that of the oral cavity, CBC, complete coagu-
logram, serum ferritin level, G6PD (glucose 6-phosphate 
dehydrogenase) level, anti-nucleus factor (ANF), rheuma-
toid factor, Lues serology (RSS and Fta-ABS), anti-HIV 1 
and 2, serum dosage of immunoglobulins (Ig) A, G and 
M, C reactive protein.
Inclusion criteria:
- Clinical history matching signs of RAS, i.e, outbre-
aks of oral cavity aphthoid lesions, with monthly periodi-
city (or less), for at least two years;
- Aphthoid lesion on the oral mucosa;
- No changes in the exams ordered according to 
protocol;
- Absence of clinical and/or laboratorial signs ma-
tching those of systemic disease with oral lesions.
- No use of topical steroid for at least two weeks 
before the biopsy.
Exclusion criteria:
- Clinical history different from that of RAS;
- Presence of alterations in the tests ordered in the 
protocol;
- Clinical and/or laboratorial signs matching those 
from a systemic disease with oral lesion.
-Use of topical steroid for at least two weeks prior 
to biopsy.
In order to rule out other diseases that affect the 
oral cavity and make the differential diagnosis with RAS 
(Behçet’s disease, Pemphigus and Pemphigoid, Erythema 
multiforme etc.) the lesion was biopsied, a fragment of 
perilesional tissue was collected for direct immunofluo-
rescence (DIf).
Biopsy was carried out under injected anesthesia 
with 2% xylocaine without vasoconstrictor, by using a 
4mm punch tool, on the mucosa adjacent to the lesion 
(perilesional) for DIf and another fragment was harvested 
at the transition area between the ulceration and the lesion 
area of the mucosa for histology purposes.
The fragment for histology was placed in a proper 
container with 10% formaldehyde.
The external surface of the perilesional epithelium 
harvested for DIf, dyed with methylene blue for better 
identification. The fragment collected was sent in a gauze 
wet in 0.9% saline solution, to the Skin Immunopatho-
logy Laboratory of the Dermatology Department at the 
HC-FMUSP.
These fragments were frozen with inclusion medium 
(Tissue Tek, Leica, Germany), wrapped around aluminum 
foil and taken to the freezer at -20°C until the time for 
processing.
They were then cut in cryostat, at a temperature 
of -20ºC (cryo-section). Three cross-sections from each 
patient, 4 microns-thick were placed on albumin-loaded 
slides.
For the immune reaction, the slides were placed in 
a wet chamber, at room temperature, and on the cross-
sections we added the conjugated (anti human immuno-
globulins produced in immunized animals and marked 
with fluorescein isothiocyanate). The conjugated material 
was diluted in TBS-calcium (TBS-Ca++) (“trisma base so-
lution”, pH 7,5) with 3 mg% Evans Blue Dye (Interlab). 
We used anti human IgA from SIGMA (1:20 dilution); anti- 
human IgM, also from SIGMA (1:20 dilution); anti human 
IgG from SIGMA (1:130 dilution) and anti human C3c 
from DAKO (1:40 dilution). After a 30-minute incubation 
period, the slides were washed in TBS for 2 ten-minute 
periods each.
In order to setup the slides we used buffered glyce-
rin (pH 9/ 0.5M) and glass lamina. The slide was read in a 
epiluminescence HBO 50w Zeiss microscope (CB12 filter), 
with a 10x eyepiece and 16x and 40x lenses.
RESULTS
In our series, nine patients were males and 14 
were females. Their ages ranged between 18 and 70 years 
(mean of 36.14 years, standard deviation of 15.33 years). 
All histology exams showed the presence of an ulcerated 
lesion on the mucosa, followed by unspecific chronic and 
acute inflammatory process on the submucosa. Routine 
dyeing and the investigation for fungi and BAAR were 
all negative, as were the immunohistochemical analysis. 
Of the 23 samples sent for Dif, only one sample showed 
mild C3 granulous presence in the basal membrane zone. 
As for IgG, IgM and IgA all the 23 samples did not show 
specific fluorescence in the basal membrane and the vessel 
walls (Figure 3).
DISCUSSION
The major role of direct immunofluorescence is to 
identify antibodies and other inflammatory proteins in the 
region damaged by disease and thus confirm or rule out 
the clinical/diagnostic suspicion of a lesion of etiology 
associated with humoral immunity disorders23.
Therefore, we may suppose that a disease with 
positive fluorescence for immunoglobulins on the mucosa 
is associated to disorders in the production of antibodies 
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and it is auto-immune, as it happens with patients with 
pemphigus vulgaris (Figure 4)23.
Therefore, DIf is an excellent test for the differential 
diagnosis between autoimmune disorders and those that 
have no relation with changes in humoral immunity23. On 
the other hand, it is worth remembering that a negative 
fluorescence is not pathognomonic of a disease associated 
with cell immunity disorders23.
In the present investigation we carried out histology 
tests and DIf in 23 patients with RAS. Our results may be 
directly compared to those from other authors who used 
DIF in patients with RAS - as depicted on Table 1. It is 
important to notice that among all the papers mentioned, 
ours is the one with the most studies with DIf. 
Donatsky and Dabelsteen16 used direct immunoflu-
orescence to study the biopsy of 16 patients with RAS, and 
they found IgG in the basal membrane of 14 patients, all 
had C3 deposits and there was no specific fluorescence 
for IgM and IgA. On the vessel walls there were no IgG, 
IgM and IgA markers.
Significant presence of C3 in the basal membrane 
was also found by Ullman and Gorlin17. In their study, five 
of 10 patients had this result; however in this region they 
did not find fluorescence for IgG, IgM and IgA. Vessel walls 
were negative for IgG; positive in 6 patients for IgM; in 2 
patients for IgA; and all 10 patients were positive for C3.
Studying a population similar to ours, comprising 22 
patients, VanHale et al.18 did not find IgA on vessel walls, 
nor in the basal membrane zone. IgG was also negative 
on vessel walls. IgM was positive in only one case both 
in the basal membrane as well as on vessel walls. As to 
the presence of C3, it was positive in six cases on vessel 
walls and seven on the basal membrane zone. 
Malmström et al.19 found no fluorescence for IgM, 
IgG and IgA in all 16 cases assessed; however, in 15 of 
them there was C3 fluorescence along vessel walls.
In 17 cases, Reimer et al.20 did not find fluorescence 
on the basal membrane for IgG, IgA and IgM; however, 
in six cases there was fluorescence for C3. The vessel 
walls did not present fluorescence for igG and IgA; and 
fluorescence was present in 4 cases for IgM and 13 cases 
for C3.
Our study with direct immunofluorescence in 23 pa-
tients is in conflict with the findings of these two authors16,17 
and in partial agreement with those from VanHale et al., 
Malmström et al. and Reimer et al.18,19,20. In our series we 
could not find specific fluorescence for igG, IgA and Igm 
on vessel walls and also on the basal membrane zone. In 
only one case we observed C3 fluorescence, even then it 
was mild in the basal membrane. 
It is important to stress that the patients who par-
ticipated in this study did not use any drug before the 
biopsy was made since false-negative results may be 
found if the region is treated with topical steroids prior 
to the biopsy23.
On the other hand, our results are in agreement 
with those from Lehner15 and Sistig el al.4, who were 
also unable to prove DIf positiveness in patients with 
RAS. These authors do not agree with the statement that 
RAS is a humoral response, they believe it is an ulcerative 
process triggered by cellular immunity.
As recently described by Natah et al.24 Scully et al.25, 
RAS immunopathogenesis involves an immune response 
mechanism mediated by cells, generation of T-cells and 
tumor necrosis factor alpha (TNF-α) by other leucocytes 
(macrophages and mast cells). It is also known that in the 
ulcerative phase of the disease there is a predominance 
of CD8+ T cells and a reduction of CD4+ T cells on the 
mucosa affected. 
Figure 3. Negative direct immunofluorescence in recurrent aphthoid 
stomatitis
Figure 4. Positive direct immunofluorescence in Pemphigus vulgaris
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Aside from this, our findings show that DIf is para-
mount for the differential diagnosis between the atypical 
RAS and vesicobullous diseases, which provenly have 
immunocomplex deposits on the epithelium. As shown 
by Femiano et al.21, there are forms of RAS, especially the 
major type, that causes large areas of mucosal ulceration 
and may be easily mistaken with PV and MMP, causing 
important diagnostic problems, preventing proper treat-
ment in due time
CONCLUSION
Based on our findings, we conclude that: 
1) DIf is negative on the perilesional mucosa of 
RAS patients. This data strengthens the hypothesis that 
the disease is especially associated with cell immunity 
disorders;
2) DIf is important in the differential diagnosis of 
atypical RAS (when the test is negative) and vesicobullous 
diseases (when the fluorescence is positive on the oral 
epithelium).
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